Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
Sign Up to like & getrecommendations! Published in 2018 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.8b00213
Abstract: GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets and enteroendocrine L-cells, and, when activated, elicits increased insulin secretion only in the presence of elevated glucose levels. We recently reported the discovery of… read more here.
Keywords: gpr40; discovery 6226; full agonist; gpr40 full ... See more keywords
Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Toxicology"
DOI: 10.1080/15563650.2022.2028802
Abstract: Abstract Introduction Patients with opioid use disorder may have difficulty transitioning from full-agonist opioids to sublingual buprenorphine due to the risk of precipitated opioid withdrawal. Novel strategies have been developed to facilitate this transition, including… read more here.
Keywords: sublingual buprenorphine; transdermal buprenorphine; buprenorphine; full agonist ... See more keywords
Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Toxicology"
DOI: 10.1080/15563650.2025.2553811
Abstract: Abstract Introduction Treatment with buprenorphine is challenging to initiate in hospitalized patients receiving full agonist opioids because of the risk of precipitated opioid withdrawal. We describe clinical outcomes of precipitated withdrawal, incidence and rate of… read more here.
Keywords: transdermal buprenorphine; agonist opioids; buprenorphine; hospitalized patients ... See more keywords
Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of addiction medicine"
DOI: 10.1097/adm.0000000000001136
Abstract: OBJECTIVES Persons with opioid use disorder (OUD) suffer disproportionately from morbidity and mortality related to serious addiction-related infections requiring hospitalization. Long-acting buprenorphine (LAB) is an underused medication for OUD that may facilitate linkage to care… read more here.
Keywords: including methadone; agonist opioids; low dose; buprenorphine ... See more keywords
Predictors of response to full agonist opioids in enriched enrollment randomized withdrawal clinical trials: a participant-level data meta-analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Pain"
DOI: 10.1097/j.pain.0000000000003803
Abstract: ABSTRACT This study aims to identify predictors of success in treating chronic pain patients with full agonist opioids by analyzing harmonized individual patient data from 5594 participants in 9 enriched enrollment randomized withdrawal clinical trials… read more here.
Keywords: agonist opioids; randomized withdrawal; withdrawal clinical; enriched enrollment ... See more keywords
Partial Agonist, Full Barrier: A Case-Based Discussion on Challenges with Buprenorphine in Chronic Pain Management.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of opioid management"
DOI: 10.5055/bupe.24.rpj.1030
Abstract: BACKGROUND More patients are on chronic opioids, as patients who were initially started on full agonist opioids for cancer-related pain are living longer. Despite doing well from the cancer stand- point, some patients have difficulty… read more here.
Keywords: agonist opioids; pain; full agonist; agonist ... See more keywords